Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | EYA2 | O00167 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5024411 | 0.83 | PAOX (0.35) | BLMLMNAPMP22ALOX15 | |
| SCHEMBL18202047 | 0.83 | TDP1 (0.36) | TDP1EYA2APPACEBLM | |
| SCHEMBL29898283 | 0.80 | PAOX (0.33) | BLMLMNAPMP22ALOX15 | |
| SCHEMBL2687920 | 0.80 | TDP1 (0.43) | TDP1EYA2APPACEBLM | |
| SCHEMBL30241145 | 0.79 | CA12 (0.44) | TDP1EYA2APPACEBLM | |
| SCHEMBL28637693 | 0.79 | TDP1 (0.40) | TDP1EYA2APPACEBLM | |
| SCHEMBL27712995 | 0.79 | TDP1 (0.40) | TDP1EYA2APPACEBLM | |
| SCHEMBL17816490 | 0.78 | FFAR3 (0.36) | TDP1EYA2APPACEBLM | |
| Water SCHEMBL7765705 | 0.78 | TDP1 (0.41) | TDP1EYA2APPACEBLM | |
| Water SCHEMBL7765711 | 0.78 | TDP1 (0.41) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015011-A1 | PEPTIDE NUCLEIC ACIDS HAVING ANTIBACTERIAL ACTIVITY | NIELSEN, Peter Eigil (DK) | 2000-07-05 | — | — | EP | claimed |
| WO-1999013893-A1 | PEPTIDE NUCLEIC ACIDS HAVING ANTIBACTERIAL ACTIVITY | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-25 | — | — | WO | claimed |
| US-20250360158-A1 | OLIGONUCLEOTIDE ANALOGUE FORMULATIONS | NEUBASE THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240132628-A1 | OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE | NEUBASE THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-107074911-B | Peptide nucleic acid monomers and oligomers | 优基艾森斯股份公司 | 2020-11-03 | — | — | CN | disclosed |
| US-9951093-B2 | Chiral compounds substituted with phosphonic acid ester functions or phosphonic acid functions | UGISENSE AG (DE) | 2018-04-24 | — | — | US | disclosed |
| CN-107074911-A | Peptide nucleic acid monomer and oligomer | 优基艾森斯股份公司 | 2017-08-18 | — | — | CN | disclosed |
| US-20170166900-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | UGISENSE AG (DE) | 2017-06-15 | — | — | US | disclosed |
| US-20130131019-A1 | CHIRAL COMPOUNDS SUBSTITUTED WITH PHOSPHONIC ACID ESTER FUNCTIONS OR PHOSPHONIC ACID FUNCTIONS | UGICHEM GMBH (AT) | 2013-05-23 | — | — | US | disclosed |
| EP-1074559-B1 | Peptide nucleic acids | BUCHARDT OLE (DK) | 2011-07-06 | — | — | EP | disclosed |
| US-20100022478-A1 | CHIRAL COMPOUNDS SUBSTITUTED WITH PHOSPHONATE ACID ESTER FUNCTIONS OR PHOSPHONIC ACID FUNCTIONS | UGICHEM GMBH (AT) | 2010-01-28 | — | — | US | disclosed |
| WO-1998003542-A1 | PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY | BUCHARDT, DORTE (DK) | 1998-01-29 | — | — | WO | disclosed |
| WO-1996035705-A1 | INHIBITION OF TRANSCRIPTION FACTOR-MEDIATED TRANSCRIPTIONAL ACTIVATION BY OLIGOMER STRAND INVASION | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-14 | — | — | WO | disclosed |
| US-5539083-A | FROM HALOACETYL HALIDE OR SULFONYLACETYL HALIDE, PROTECTED ALKYLENEDIAMINE, AND A DERIVATIVE OF A NUCLEIC ACID BASE | ISIS PHARMACEUTICALS, INC. (US) | 1996-07-23 | — | — | US | disclosed |
| EP-0699208-A1 | NOVEL PEPTIDE NUCLEIC ACIDS | NIELSEN, Peter Eigil (DK) | 1996-03-06 | — | — | EP | disclosed |
| WO-1995029921-A1 | ACTIVATED ESTERS OF 1-PHENYLPYRAZOLIN-5-ONE FOR LABELLING AMINE-FUNCTIONALIZED MOLECULES | PERSEPTIVE BIOSYSTEMS, INC. (US) | 1995-11-09 | — | — | WO | disclosed |
| WO-1995004068-A1 | OLIGOMERS FOR MODULATING HUMAN IMMUNODEFICIENCY VIRUS | ISIS PHARMACEUTICALS, INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| WO-1995003833-A1 | OLIGOMERS FOR MODULATING PROTEIN KINASE C | ISIS PHARMACEUTICALS, INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| WO-1994028720-A1 | OLIGOMERS FOR MODULATING RAS ONCOGENE | ISIS PHARMACEUTICALS, INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994025477-A2 | NOVEL PEPTIDE NUCLEIC ACIDS | NIELSEN PETER E (DK) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166900-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | DTYMK, POLM, PNKP | TDP1 615/4885EYA2 4580/4885APP 190/4885 |
| US-20130131019-A1 | CHIRAL COMPOUNDS SUBSTITUTED WITH PHOSPHONIC ACID ESTER FUNCTIONS OR PHOSPHONIC ACID FUNCTIONS | PNP, PHOSPHO1, PNKP | TDP1 795/4885EYA2 681/4885APP 1695/4885 |
| US-20100022478-A1 | CHIRAL COMPOUNDS SUBSTITUTED WITH PHOSPHONATE ACID ESTER FUNCTIONS OR PHOSPHONIC ACID FUNCTIONS | PNP, PHOSPHO1, PNKP | TDP1 913/4885EYA2 920/4885APP 2166/4885 |
| US-20250360158-A1 | OLIGONUCLEOTIDE ANALOGUE FORMULATIONS | SNRPA1, SNRPA, SNRPE | TDP1 15/4885EYA2 561/4885APP 1801/4885 |
| US-20240132628-A1 | OLIGONUCLEOTIDE ANALOGUE THERAPEUTICS FOR TREATMENT OF NEUROMUSCULAR DISEASE | SMN1; SMN2, POLRMT, TARDBP | TDP1 13/4885EYA2 1872/4885APP 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.